They have for clinically definate MS but for CIS (clinically isolated Syndrome) the practice in Health Canada is to give Rebif weekly rather than three times a week. The same practice is present in the US for one dose of Rebif or one dose of Avonex weekly for CIS at the present. This trial, as I understand it, is to broaden the scope of treatment beyond the two countries and try to set a standard for early treatment worldwide.